Failure-to-success ratios, transition probabilities and phase lengths for prophylactic vaccines versus other pharmaceuticals in the development pipeline

Vaccine

Volumn 29, Issue 51, 2011, Pages 9414-9416

  Davis, Matthew M ^a,b,c   Butchart, Amy T ^a   Wheeler, John R C ^b   Coleman, Margaret S ^c   Singer, Dianne C ^a   Freed, Gary L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Failure; Industry; Prophylactic; Research; Success; Vaccine

Indexed keywords

VACCINE;

ARTICLE; COHORT ANALYSIS; DRUG INDUSTRY; FOLLOW UP; HUMAN; MEDICAL RESEARCH; PHASE TRANSITION; PRIORITY JOURNAL; PROPHYLAXIS;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH; TREATMENT FAILURE; VACCINES;

EID: 81955167436     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.128     Document Type: Article

References (8)

1. Coleman M.S., Sangrujee N., Zhou F., Chu S. Factors affecting US manufacturers' decisions to produce vaccines. Health Affairs 2005, 24:635-642.
2. Institute of Medicine Vaccine financing in the 21st century 2003, National Academies Press, Washington, DC.
3. DeBrock L., Grabowski H. Economic aspects of vaccine innovation and manufacturing. Vaccine supply and innovation 1985, National Academies Press Institute of Medicine, Division of Health Promotion and Disease Prevention, Washington, DC.
4. Davis M.M., Butchart A.T., Coleman M.S., Singer D.C., Wheeler J.R.C., Pok A., et al. The expanding vaccine development pipeline, 1995-2008. Vaccine 2010, 28:1353-1356.
5. Davis M.M. Price as a double-edged sword in the golden era of vaccines. Human Vaccines 2010, 6:689-693.
6. DiMasi J.A., Hansen R.W., Grabowski H.G., Lasagna L. Cost of innovation in the pharmaceutical industry. Jour Health Economics 1991, 10:107-142.
7. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. Jour Health Economics 2003, 22:151-185.
8. Adams C.P., Brantner V.V. Estimating the cost of new drug development: is it really 802 million?. Health Affairs 2006, 25:420-428.